With 64,050 new diagnoses and 50,550 deaths in the US in 2023, pancreatic ductal
adenocarcinoma (PDAC) is among the most lethal of all human malignancies. Early …

Pancreatic cancer is one of the worst prognoses of all malignancies. More than 40,000
deaths a year from this disease are observed in European Union alone. The only possibly …

Metabolomics is a rapidly growing field of research used in the identification and
quantification of the small molecule metabolites within an organism, thereby providing …

Simple Summary Pancreatic cancer is a significant problem worldwide. Most cancers are
diagnosed at an advanced stage. Limited knowledge of the pathogenesis of pancreatic …

Purpose pancreatic adenocarcinoma is the fourth leading cause of cancer related deaths
due to its aggressive behavior and poor clinical outcome. There is a considerable variability …

Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is
no blood test for early detection and diagnosis of this disease. Several research groups …

Pancreatic cancer (PC) is the fourth leading cause of cancer death in the United States, with
4% survival, 5 years after diagnosis. Patients with pancreatic cancer are usually diagnosed …

Background A reliable biomarker to detect pancreatic ductal adenocarcinoma (PDAC)
continues to be elusive. With employing metabolomics we hypothesize that a broader …

As the most malignant tumor, the prognosis of pancreatic cancer is not ideal even in the
small number of patients who can undergo radical surgery. As a highly heterogeneous …

The availability of robust classification algorithms for the identification of high risk individuals
with resectable disease is critical to improving early detection strategies and ultimately …